Minnesota's Office of Cannabis Management marked one year of state-licensed sales on September 15 with a headline number: more than $250 million in combined adult-use and medical purchases. The number is accurate. It is just not the one operators should plan around.
The Number Behind The Number
Roughly $100 million of that total came from medical patients. Adult-use, the market Minnesota spent two years building after legalization in 2023, brought in about $150 million from its September 16, 2025, launch through mid-September 2026, according to OCM. Before launch, the MJBiz Factbook had projected $430 million in Minnesota adult-use sales for calendar 2026.
Per resident, Minnesota's first year works out to about $26 in adult-use spending. Ohio, the most recent large-state launch, did more than twice that. Missouri, with a population only slightly larger than Minnesota's, topped $1.3 billion in its first year.
State | Adult-Use Launch | First-Year Adult-Use Sales | Per Resident |
|---|---|---|---|
Rhode Island | December 2022 | About $64 | |
Ohio | August 2024 | About $60 | |
Illinois | January 2020 | About $53 | |
Delaware | August 2025 | About $51 | |
Maine | October 2020 | About $44 | |
Minnesota | September 2025 | About $150 million | About $26 |
Washington | July 2014 | About $25 | |
New York | December 2022 | About $8 |
Per-resident figures are a Cannabis Professional calculation using U.S. Census Bureau population estimates for each state's launch year.
The Wall Of Shame
Minnesota's start was slow, but it was not the worst. Judged on sales per resident or on how far a state fell short of its own forecasts, three launches did worse.
New York. The state's first legal sale came in December 2022, and the first year produced about $150 million, roughly $8 per resident and less than a third of Minnesota's rate. Early projections had New York becoming the East Coast's largest adult-use market with more than $1 billion in first-year sales. A lawsuit froze equity retail licensing for months, medical operators were kept out of early adult-use and only about 40 dispensaries opened in year one. Unlicensed shops filled the gap.
Delaware. Delaware beat Minnesota per resident, but it missed its own forecast by more. First-year sales of $53.4 million landed about 81% below the $281 million its first marijuana commissioner predicted in 2023. Licensing hit a wall when the FBI declined to process the background checks the law required, and social equity licensing has been turbulent since.
Washington. The 2014 pioneer did about $180 million at retail stores in year one, roughly $25 per resident and even with Minnesota. Pot-tax revenue came in at about one-quarter of the maximum state analysts had projected. Washington gets partial credit: it had no other state's playbook to copy.
Honorable Mention: Maine took nearly four years to go from a 2016 ballot vote to its first sale, though its first-year rate of about $44 per resident still beat Minnesota's.
What Minnesota Got Right
The sales gap has clear causes. The industry spent much of year one working through limited supply and testing bottlenecks, and lawmakers raised the cannabis tax to 15% before launch. With sales tax, the total rate runs around 22%, and higher in many metro cities. Missouri's state tax on adult-use cannabis is 6%, before local add-ons.
But several Minnesota decisions are worth copying:
Medical Grew Instead Of Shrinking. Enrollment more than doubled, from about 41,000 patients to more than 90,000. Rhode Island went the other way, falling from 15,062 patients to 10,037 in its first adult-use year. Minnesota exempts medical purchases from both the cannabis tax and sales tax.
Incumbents Bridged Supply. The two medical combination licensees were allowed to wholesale adult-use product to new retailers, which kept early shelves stocked.
Supply Caught Up. Plants in the state's tracking system rose from about 72,000 at launch to about 486,000, and licensed growers now number 102.
Equity Licenses Landed. Of 369 licensed businesses, 43% are owned by verified social equity applicants. New York's equity-first plan stalled in court.
Momentum Is Real. April 2026 sales hit $25 million, up 50% from October 2025, the first full month.
Flop Or Foundation?
Not a flop. Minnesota launched late, underdelivered on forecasts and taxed itself into a price problem. It also avoided New York's paralysis, kept its medical base growing and built a supply chain that is now outrunning first-year demand.
That sets up a harder year two for operators. Nearly seven times more plants in the system means price compression is coming, and new retailers will open into a crowded field. Regulators are also telling businesses to prepare for federal hemp rule changes that could reshape the low-dose THC competition on the shelf.
For Minnesota Operators: budget for lower shelf prices, protect the medical customer base the tax exemption created and track hemp rule changes now. Year one was about getting open. Year two decides who stays open.